Company intelligence / Profile preview
Vertero Therapeutics
Woburn, Massachusetts, United Statesvertero.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate VT-5006, a first-in-class oral small molecule targeting pathological processes in the gut, shows strong safety and efficacy signals in preclinical studies for Parkinson’s disease and is scheduled to enter Phase 1 in Q4 2025. The pipeline also includes an early-stage asset addressing bile acid dysregulation for an undisclosed indication.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Vertero Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vertero Therapeutics.